IMMUNOTHERAPY

Many tumors are resistant to chemotherapy and are capable of inactivating the body’s immune response, posing a threat of recurrence and progression of the disease. Activation of the patient’s immune system during cellular immunotherapy is a useful additional way to combat cancer, allows to increase of the relapse-free period, and regulates the timing of subsequent lines of chemotherapy.

The main task of activating antitumor immunity is performed by the patient’s own dendritic cells, which are specialized and most powerful antigen-presenting cells of our body and are capable of initiating a targeted immune response against a specific tumor.

The biomaterial for the production of dendritic cells is venous blood (volume about 50 ml). Individual native tumor antigens (tumor lysates), as well as synthetic standardized tumor-associated antigens, are used as antigenic material for the creation of a biomedical cell product (BMCP) based on dendritic cells.

The clinical effect of immunotherapy with dendritic cells is manifested by the stabilization of the tumor process (in 40-50% of cases), sometimes with partial or complete regression (5-15%), and can last on average from 3 months to a year. The maximum clinical effect can be expected with the course administration of BMCP based on dendritic cells in an adjuvant mode after removal of the primary focus (after surgery) to prevent tumor recurrence and destroy invisible micrometastases.

You can get the additional information and make an appointment with specialists at the following phone numbers:
+375 (17) 378 18 21
+375 (44) 574 18 21 (Viber, WhatsApp, Telegram)
e-mail: med@ibce.by